A total of 499 patients (n = 336 male, n = 163 female) with a median age of 58 years treated with CD19-directed CAR T-cell therapy for ALL (n = 134) or NHL (n = 365) across clinical trials conducted between 2015 and 2020 were included in this study. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.